1 Viral load dynamics in asymptomatic and symptomatic patients during Omicron

2 BA.2 outbreak in Shanghai, China, 2022: a longitudinal cohort study

- 3 Jingwen Ai^{1†}, Jiaxin Zhou^{2†}, Yang Li^{1†}, Feng Sun^{1†}, Shijia Ge^{1†}, Haocheng Zhang^{1†},
- 4 Yanpeng Wu², Yan Wang², Yilin Zhang¹, Hongyu Wang¹, Jianpeng Cai¹, Xian Zhou¹,
- 5 Sen Wang¹, Rong Li¹, Zhen Feng¹, Xiangyanyu Xu², Xuemei Yan², Yuchen Zhao²,
- 6 Juanjuan Zhang^{2,3}, Hongjie Yu^{1, 2*}, Wenhong Zhang^{1,3*}
- 7

8 Affiliations:

- 9 1. Department of Infectious Diseases, Shanghai Key Laboratory of Infectious
- 10 Diseases and Biosafety Emergency Response, National Medical Center for Infectious
- 11 Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, China
- 12 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety,
- 13 Ministry of Education, Shanghai, China
- 14 3. Shanghai Huashen institute of microbes and infections. Shanghai, China
- 15
- 16 **Running title:** Viral load dynamics in COVID-19 patients
- 17

18 **Corresponding authors:**

- 19 Hongjie Yu, yhj@fudan.edu.cn
- 20 Wenhong Zhang, zhangwenhong@fudan.edu.cn
- 21 *†*These authors contributed equally.

22 *These authors were joint senior authors contributed equally to this work.

23

- 24 Word count (abstract): 247
- 25 Word count (main text): 3121
- 26
- 27 Abstract
- 28 Backgrounds:
- 29 The SARS-CoV-2 virus has caused global outbreaks, including the recent Omicron BA.2
- 30 wave in Shanghai in spring 2022. While, the viral load dynamic of Omicron infections with
- 31 different clinical severity was still unclear.
- 32

33 Methods:

- 34 A prospective cohort was conducted on 48,830 hospitalized COVID-19 patients in three
- bospitals in Shanghai, China, from 23 March and 15 May 2022. Regular nucleic acid testing
- 36 was performed and the Cycle threshold (Ct) value tested by RT-PCR was used as a proxy of
- 37 viral load. The viral load dynamic by different clinical severity since initial detection and the
- 38 risk factors were analyzed.
- 39
- 40 Results:

| 41 | The study included 31% asymptomatic cases, 68% mild-moderate cases, 1% severe cases, |
|----|---|
| 42 | 1.29% critical and fatal cases. 57% of patients tested positive upon admission, average Ct |
| 43 | value remained stable with peak viral concentrations occurring at 4 days (median Ct value of |
| 44 | 27.5), followed by a decrease with a viral shedding time (VST) of 6.1 days (IQR, 4.0-8.8 days). |
| 45 | Omicron viral load varied by age and clinical severity, but peak Ct values occurred at similar |
| 46 | times. Unvaccinated status, age over 60, and comorbidities were associated with higher peak |
| 47 | viral concentrations and longer shedding durations. Asymptomatic cases had a 40% |
| 48 | contagious probability within 6 days of detection. Mild-moderate cases and severe cases had |
| 49 | a 27%, >50% probability of infectiousness post-symptom resolution, respectively. |
| 50 | |
| 51 | Conclusion: |
| 52 | The initial Ct value could forecast severe consequences. Unvaccinated older people with |
| 53 | specific comorbidities are the high-risk groups associated with high viral load and long |
| 54 | shedding duration. |
| 55 | |
| 56 | Key words: |
| | |

57 COVID-19; Omicron; BA.2; Viral load dynamics; Viral shedding time

58 Background

| 59 | Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory |
|----|---|
| 60 | syndrome coronavirus 2 (SARS-CoV-2), has resulted in unprecedented impact worldwide. |
| 61 | Viral load, as a key determinant of viral shedding, is shown to correlate with infectivity, |
| 62 | transmissibility, and pathogenicity. Understanding the SARS-CoV-2 viral load trajectory is |
| 63 | crucial for developing epidemiological control strategies and optimizing clinical management |
| 64 | of COVID-19 patients. The cycle threshold (Ct) value obtained by reverse |
| 65 | transcription-polymerase chain reaction (RT-PCR) was widely used as a surrogate marker for |
| 66 | infectiousness due to high correlation between RNA viral load and the presence of infectious |
| 67 | virus ¹ . |
| 68 | Since March 2022, a local outbreak of the Omicron sub-lineage BA.2 ^{2, 3} had occurred in |
| 69 | Shanghai, resulting in over 0.6 million laboratory-confirmed infections of early June ⁴ . While |
| 70 | previous studies have revealed some viral load characteristics of ancestral SARS-CoV-2 and |
| 71 | other variants of concern (VOC) $^{5-10}$, Omicron variant has shown dramatic changes in viral |
| 72 | dynamics and clinical features. Some previous studies mainly focused on the effect of |
| 73 | vaccines on viral dynamics of Omicron or only analyzed in-depth the viral dynamics of |
| 74 | symptomatic patients ¹¹⁻¹⁵ . Several studies included asymptomatic individuals but the size |
| 75 | numbers were limited ^{14, 16} or only presented the viral shedding time ¹⁷ . One study analyzed the |
| 76 | viral dynamics in detail focused on mild cases ¹⁵ . Evidences about peak viral load and viral |
| 77 | shedding dynamics of Omicron are still sparse and there is a lack of multicenter evidence of |

- viral dynamics on a broad spectrum of diseases including asymptomatic, mild and severe and
- 79 death cases supporting by large sample sizes. This multicenter study aims to providing a
- 80 comprehensive description of viral kinetic characteristics about Omicron BA.2 among patients
- 81 with a wide disease spectrum ranging from asymptomatic to critically ill or death, and to
- 82 identify the possible risk factors affecting viral characteristics.
- 83

84 Methods

85 Study design and participants

| 86 | 5 The study | enrolled a total | of 48830 COVID-1 | 9 cases, where all | patients were | admitted to the |
|----|-------------|------------------|------------------|--------------------|---------------|-----------------|
|----|-------------|------------------|------------------|--------------------|---------------|-----------------|

- 87 three designated hospitals/makeshift hospitals in Shanghai from 23 March to 15 May 2022,
- 88 and their RT-PCR testing results were collected during the hospitalization. For each
- 89 participant, serial samples of nasopharyngeal swabs were collected from all the participants
- 90 during the hospitalization according to clinical need. Clinical information such as the
- 91 vaccination history, including the vaccination dates and vaccine type, the date of illness onset,
- 92 and duration of hospitalization were well documented from clinical records. Personal
- 93 demographic information was also obtained from the questionnaire reported by patients or

94 guardians.

- 95 COVID-19 cases were defined as individuals who tested positive for SARS-CoV-2 by
- 96 RT-PCR. The degree of severity of the patient was categorized according to the clinical
- 97 manifestation and the supportive measures used within the healthcare system according to a

| 98 | revised WHO clinical progression scale ¹⁸ . Specifically, the asymptomatic type had no clinical |
|---|--|
| 99 | symptoms and no pneumonia manifestation can be found in imaging. The mild-moderate type |
| 100 | had clinical symptoms or shows abnormalities in lung imaging and received no oxygen |
| 101 | therapy. Patients who received oxygen therapy by mask or prongs, or received non-invasive |
| 102 | ventilation (NIV) or high flow oxygen therapy would be categorized as severe type. Those who |
| 103 | received intubation and mechanical ventilation or even died were defined as 'Critical-death' |
| 104 | patients. |
| 105 | |
| 106 | Laboratory confirmation of COVID-19 by reverse-transcription polymerase chain |
| | |
| 107 | reactions |
| 107 108 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) |
| 107 108 109 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented |
| 107 108 109 110 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). |
| 107 108 109 110 111 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates |
| 107 108 109 110 111 112 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates of relative viral genomic loads, and Ct ≤35 was considered positive. The viral load level was |
| 107 108 109 110 111 112 113 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates of relative viral genomic loads, and Ct ≤35 was considered positive. The viral load level was inversely correlated with Ct value which is a low viral load characterized by a high Ct and a |
| 107 108 109 110 111 112 113 114 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates of relative viral genomic loads, and Ct ≤35 was considered positive. The viral load level was inversely correlated with Ct value which is a low viral load characterized by a high Ct and a high viral load characterized by low Ct values. Additionally, several researches revealed that |
| 107 108 109 110 111 112 113 114 115 | reactions The sampling and detection procedure was described in supplementary material. The (Ct) values of both ORF1ab and N genes of SARS-CoV-2 were collected but results are presented only for N gene since the patterns observed for both genes were similar (unpublished data). The Ct values of real-time RT PCR tests of nasopharyngeal species were used as surrogates of relative viral genomic loads, and Ct ≤35 was considered positive. The viral load level was inversely correlated with Ct value which is a low viral load characterized by a high Ct and a high viral load characterized by low Ct values. Additionally, several researches revealed that the cultural positive proportion of omicron virus from respiratory tract specimens was under 5% |

116 with Ct value of 32^{16, 19-23}, proving the unsuccessful to recover infectious virus when Ct value

- 117 of 35. Thus, we chose the Ct value of 35 as positive threshold to exploring the correlation
- 118 between CT value and infectiveness in our study.

119

120 Statistical analysis

- 121 Demographic information including age, gender, status of underlying disease, vaccination
- 122 history at admission of patients was described in total as well as by clinical severity. Baseline
- 123 characteristics among four clinical severity groups was compared using Chi-square test for
- 124 discrete variables and the Wilcoxon test for continuous variables.
- 125 The kinetic of viral load of patients since initial detection was described by total, by clinical
- severity, by age groups, by vaccination status, and by comorbidities using mean and 95%
- 127 confidence interval (CI). Virus shedding time (VST) was defined as the interval between the
- 128 date of initial detection of PCR and the date of subsequent first negative PCR test. For
- 129 patients with a positive result at their last follow-up, VST was right censor and was defined as
- 130 the interval between the date of the first positive PCR test and date of the last positive test.
- 131 The intervals of VST, intervals between symptom onset and first PCR positive, and the
- 132 intervals between symptom resolution and first PCR positive were estimated using gamma,
- 133 Weibull, and lognormal distributions based on AIC considering censor data. The median and
- 134 interquartile range (IQR) were described for each interval.

135 The viral proliferation stage and viral clearance stage were classificated by the peak

136 concentration of viral load, with the former is the phase before peak and the latter is the phase

| 137 | after peak. Thus, peak concentration of viral load and VST were described as essential index |
|-----|--|
| 138 | of the kinetic by total and by several factors mentioned above respectively. Multivariate linear |
| 139 | regression and interval regression were used to investigate the risk factors associated with |
| 140 | peak Ct value and VST. The patients with long VST (> 30 days) were excluded in baseline |
| 141 | analysis. The comparison of baseline characteristics between participants and excluded |
| 142 | patients was conducted. The statistical analyses were conducted by R (version 4.14). |
| 143 | |

144 Results

| 145 | As of May 15 th , 2022, 48830 participants were included, with 31% of asymptomatic |
|-----|---|
| 146 | participants, 68% of mild-moderate cases, 1% severe cases, 0.29% of critical cases or death |
| 147 | cases, respectively. The baseline characteristics of participants at admission were described |
| 148 | by clinical status in table 1. The median age was 45 years old (IQR, 32-55 years) and 63% of |
| 149 | participants were female. 21% of patients had at least one comorbidity, with hypertension |
| 150 | (14%), diabetes (5%) and cardiovascular diseases (2%) being the top three comorbidities. |
| 151 | The majority (88%) of patients had at least one-dose vaccination. Patients with severity of |
| 152 | severe or above were older and with more comorbidities, but less vaccination coverage than |
| 153 | asymptomatic and mild-moderate cases (p <0.001). The excluded patients had worsened |
| 154 | clinical severity status but similar gender proportion and age distribution comparing to the |
| 155 | participants (table S1). |

156 Viral shedding dynamic and viral load concentration

| 157 | On the day of initial detection 57% of patients were positive with an average Ct value of 33 (95% |
|---------------------------------|--|
| 158 | CI, 31-34). This data remained stable within the first 4 days, before the viral load declined |
| 159 | significantly on an average of 6.1 days (IQR, 4.0-8.8 days), and slowly decreased further |
| 160 | within the next 3 weeks (Fig. 1A, B). The corresponding negative proportion would also gently |
| 161 | approach 100% after a rapid growth to 74% (95% CI, 73-74) by day 10 (Fig. 1A). The peak |
| 162 | occurrence of viral concentrations was within the first 4 days (IQR, 3-6 days) with a median Ct |
| 163 | value of 27.5 (IQR, 23.4-32.1) (Fig. 1C). |
| | |
| 164 | Severity-specific viral shedding dynamic |
| 164 165 | Severity-specific viral shedding dynamic Patients with worsened clinical severity were observed to have higher viral loads with average |
| 164 165 166 | Severity-specific viral shedding dynamic Patients with worsened clinical severity were observed to have higher viral loads with average Ct values of 35 (95% Cl, 33-37), 32 (95% Cl, 27-40), 27 (95% Cl, 20-34) for asymptomatic |
| 164 165 166 167 | Severity-specific viral shedding dynamic Patients with worsened clinical severity were observed to have higher viral loads with average Ct values of 35 (95% Cl, 33-37), 32 (95% Cl, 27-40), 27 (95% Cl, 20-34) for asymptomatic cases, mild-moderate, and severe patients, respectively, on the initial detection day, and 21 |
| 164 165 166 167 168 | Severity-specific viral shedding dynamic Patients with worsened clinical severity were observed to have higher viral loads with average Ct values of 35 (95% Cl, 33-37), 32 (95% Cl, 27-40), 27 (95% Cl, 20-34) for asymptomatic cases, mild-moderate, and severe patients, respectively, on the initial detection day, and 21 (95% Cl, 20-27) for critical patients one day since initial detection (p < 0.001). As the virus |

170 days, except for similar Ct values between severe and critical groups during 0-5 days (Fig.

171 2A). The viral load of patients in the critical group showed a monotonically diminishing from a

172 Ct value of 21 to 38 (95% CI, 37-40) with the longest viral shedding duration of 14.5 days (IQR,

173 7.9-23.4) compared to other groups. Conversely, for asymptomatic, mild-moderate, and

severe cases, the average viral load was stable or significantly increasing within 4, 2, and 4

175 days, respectively, then dropped significantly with corresponding Ct values turning negative

- 176 by day 5.2 (IQR: 3.2-8.0), 6.4 (IQR: 4.4-9.0), and 12.7 (IQR: 8.6-17.1). For patients with
- 177 positive Ct values, the times of peak Ct value occurrence were similar among different groups
- 178 (4-5 days), but peak concentrations showed gradual differences among the four clinical
- 179 severity groups (p<0.001) (Fig. 2C).
- 180 Age-specific viral shedding dynamic
- 181 Age-specific viral shedding dynamics revealed that elder patients had higher viral load and a
- 182 longer viral shedding duration than the youngesters during most days of viral shedding,
- 183 despite the lack of significant grade trend for four age groups in the first days (Fig. 2). On the
- 184 initial detection day, the Ct value of the 60-79 years old group was lower than that of the 80+
- 185 years old group (25, 95% CI: 21-28; 30, 95% CI: 24-36, p=0.185), and was similar between
- 186 the other age groups (33, 95% CI: 32-34 on day 1; 34, 95% CI: 34-36 on day 0, p = 0.366).
- 187 Patients aged 80+ years old had the highest viral load, which increased within the first 4 days
- 188 followed by a gentle decrease before conversion by day 9.8 (IQR, 5.9-14.6). Patients aged
- 189 18-59 and 60-79 years old experienced a VST of 6.2 days (IQR, 4.0-8.8) and 6.9 days (IQR,
- 190 4.4-10.2), respectively. In contrast, patients under 18 years old had a shortest shedding
- duration of 5.6 days (IQR, 3.6-8.3). Moreover, for patients with positive CT values, the time of
- 192 peak CT value occurrence was similar among different groups (4-5 days), but peak viral
- 193 concentrations showed an increasing trend with age (p<0.001). The results of viral shedding
- 194 dynamic stratified by age and clinical severity were described in supplementary material.

Factors associated with reduction in peak viral load and durations of viral shedding time

- 197 According to the multivariate analysis, higher peak viral concentrations and longer durations
- 198 of effective viral shedding were observed in unvaccinated cases, those of older age, and with
- 199 comorbidities (Fig. 4). Hypertension, kidney disease (especially kidney dialysis and kidney
- transplantation), neurological conditions, rheumatism and psychotic conditions were
- 201 significantly correlated with higher peak viral load concentrations. Receiving at least one-dose
- 202 vaccination was significantly associated with a reduction in peak viral load and a shorter viral
- 203 shedding duration compared to the unvaccinated group. Sequential booster immunization
- was found to be more effective in reducing peak viral load and shortening viral shedding
- 205 duration than homologous booster immunization, regardless of the type of vaccine
- 206 (inactivated, ad-vectored, or protein subunit). Stratified analyses by clinical severity were
- 207 reported in the supplementary material.

208 Relationship between infectivity and symptomatic status.

- 209 Figure 5 illustrated the clinical severity-specific kinetic of positive proportion among patients
- 210 since initial detection. Asymptomatic cases had a positive proportion of 34-39% within 6 days
- 211 since initial detection, which decayed to 12% (95%CI: 10-15) after two weeks. For
- symptomatic cases, virus had already proliferation before symptom onset with lead times of
- 213 2.99, 1.56, and 2.13 days, resulting in high positive proportion of 63-66%, 67-85%, and 100%
- 214 before onset for mild-moderate, severe, and critical or death patients, respectively. For

| 215 | mild-moderate and severe patients, the proportion decayed significantly as symptom |
|-----|---|
| 216 | subsided. Mild-moderate patients decreased to 27% (95%CI: 26-28) on the day of symptom |
| 217 | resolution and below 20% after 14 days, while severe cases decayed to 76% (95%CI:70-80) |
| 218 | on the day of symptom resolution and below 20% after 24 days. In the critical or death group, |
| 219 | positive proportion maintained above 70% even after symptom resolution, until 20-30 days |
| 220 | when it decreased to 46% (95%CI: 37-55). |
| 221 | |
| | |

222

- -

223 Discussion

| 224 | Here we provided | a comprehensive of | description of | the ch | naracteristics of | Omicron BA.2 vira | ı |
|-----|------------------|--------------------|----------------|--------|-------------------|-------------------|---|
|-----|------------------|--------------------|----------------|--------|-------------------|-------------------|---|

- shedding across a wide range of disease spectra and age groups, using Ct value as a
- surrogate of viral load. Among 48830 participants, 57% were PCR test positive on the initial
- detection day, and viral load then increased significantly to peak at around 4 days after
- detection following a decreasing trend with a VST of 6.1 days. Clinical severity and age had a
- 229 clear influence on the viral shedding dynamics, as evidenced by the initial Ct value, peak Ct
- value and viral shedding duration, although the peak times were similar at 4-5 days.

- 232 It's important to note that the study participants were from the general population and couldn't
- be representative of immunocompromised individuals. Additionally, the viral load dynamic for
- the overall study population was relatively low and shedding quickly due to the large

| 235 | proportion of asymptomatic and mild-moderate cases with lower viral loads. Compared to the |
|-----|--|
| 236 | limited results on Omicron, our findings regarding the initial Ct value were similar to |
| 237 | observations of adolescent children ^{24, 25} , adults ²⁶ and elderly patients ²⁷ . Few studies have |
| 238 | reported the severity-specific Omicron viral load, and the participants in these studies had |
| 239 | different compositions of clinical severity ^{11, 15} . Lin' study focus on the effect of vaccines and it's |
| 240 | hard to compare their results with this study ¹¹ . The initial Ct value of asymptomatic and mild |
| 241 | cases was higher than Yang's study, which may be explain by the earlier isolation in our |
| 242 | study. The initial Ct value of asymptomatic cases was similar to Wu's study, while the Ct value |
| 243 | of symptomatic patients was relatively higher than that, which may be due to the high |
| 244 | consistence of fatal cases in their study and the 2-day delay in specimen collection since |
| 245 | onset ²⁸ . The peak viral load of mild-moderate patients in our study was similar to Hay's study |
| 246 | ^{15, 29} . The average peak times reported were 2.5-4.2 days since detection and 3-4 days since |
| 247 | onset ^{15, 21, 30, 31} , and the viral load turned negative after 6-8 days, which could be prolonged to |
| 248 | more than 10 days with older ages ^{17, 28, 32} . These results were similar to our findings. In |
| 249 | addition, the Ct value both at initial and the peak viral load stage in our study were higher than |
| 250 | those of ancestral, Alpha, and Delta variant in the same population ^{28, 29, 33, 34} . This |
| 251 | phenomenon has been frequently observed ^{1, 19, 20} , indicating that high transmissibility of |
| 252 | Omicron may be attributed to other mechanisms beyond viral load. |
| 253 | |

254 Accordingly, the overall Omicron infected individuals exhibited high viral load within the first

| 255 | week since initial detection indicating the highest infectious ability in the first week, a 14-day |
|-----|---|
| 256 | quarantine for infected people was an effective control as prior conducted ³⁵ . The probability of |
| 257 | infectious among asymptomatic cases was lowest during shortest infection duration |
| 258 | comparing to symptomatic cases. For mild-moderate cases, the infectious probability had |
| 259 | decayed to low level (20%) after symptom resolution. In the contrast, severe or above patients |
| 260 | had extreme high infectious proportion during more than 24 days infectious durations and |
| 261 | more than half of severe or above patients were still infectious after symptom resolution. |
| 262 | Despite the relaxation of national COVID-19 control measures in many countries, certain |
| 263 | institutions and workplaces, such as aging healthcare facilities, schools, and border entry |
| 264 | points, require ongoing vigilance with respect to the virus. For these settings, we would |
| 265 | recommend implementing graded control measures that take into account the clinical severity |
| 266 | and updating the duration of isolation or self-monitoring accordingly to reduce the impact on |
| 267 | normal life. |
| 268 | |
| 269 | According to our results, patients with worsened clinical outcomes featured a lower initial Ct |
| 270 | value post detection, peak value as well as longer shedding duration. Older age group, |
| 271 | unvaccination, with comorbidities including hypertension, kidney disease especially kidney |
| 272 | dialysis and kidney transplantation, neurological disorders, rheumatism, psychotic conditions |
| 273 | and females were both independent risk factors associated with higher peak viral |
| 274 | concentration as well as longer shedding duration, which were supported by previous |
| 275 | studies ^{21, 36-39} . A delay or dysfunction in the initial triggering of the immune reaction led by |

| 276 | aging ⁴⁰ , and higher levels of angiotensin converting enzyme 2 in alveoli of older people ⁴¹ , |
|-----|---|
| 277 | which is believed to be a receptor for novel coronaviruses, can partially explain the |
| 278 | phenomenon. Our results support that getting at least one dose of vaccination and getting |
| 279 | mixed booster could effectively reduce the peak viral load and shorten the shedding duration |
| 280 | than unvaccinated patients. |
| 281 | |
| 282 | Virus had proliferation preceding symptom onset and exhibited fastest replication in the first |
| 283 | 4-5 days since detection, implying the requirement of antiviral therapy in early phase. |
| 284 | Previous study indicated that the effect of nirmatrelvir/ritonavir treatment had minor clinical |
| 285 | effect if practiced later than 5 days after onset ⁴² , and Paxlovid lacked efficacy for severe adult |
| 286 | patients in preventing illness progressing ⁴³ . Considering the delay of onset and detection, |
| 287 | according our study, it is recommended giving timely antiviral drug within 3 days since onset |
| 288 | for mild-moderate patients, which may play better effect on decrease peak level to shorten |
| 289 | shedding duration and deduce risk developing severe outcome, particularly for high-risk |
| 290 | group. |
| 291 | |
| 292 | This study is the most comprehensive dynamic description about the viral shedding |
| 293 | characters of omicron in Shanghai outbreak, 2022 covering all age groups and wide disease |
| 294 | spectra with a sample size of over 40,000. In this study, we provided a comprehensive |
| 295 | depiction of viral shedding pattern stratified by clinical severity, age groups, number of |
| 296 | comorbidities, and vaccination status, and a quantified analysis to investigate the independent |

| 297 | risk factors associated viral shedding characters and estimation the effect. However, there are |
|-----|--|
| 298 | still some weaknesses in our study. Firstly, this is a site-selection study, although the |
| 299 | large-sample size, the participants could not represent the entire population in Shanghai, |
| 300 | China. Secondly, the clinical diagnosis information on admission was incompletely collected |
| 301 | making it impossible to respond the relationship between symptom progression and viral load |
| 302 | dynamic in individual level. Thirdly, due to unavoidable reasons, the outcome of viral |
| 303 | conversion for critical or death groups was more likely censored, resulting in fluctuation in Ct |
| 304 | dynamic in the later phase of onset and wide confidence interval of VST estimation. |
| 305 | |
| 306 | This study found that using Ct value as the proxy viral load, the viral load dynamic of Omicron |
| 307 | infected individuals presented considerable age variation and clinical severity variation. For |
| 308 | some specific workplaces, such as aging healthcare facilities and schools, the graded control |
| 309 | measures should be recommended due to possible increased clinical severity. Initial Ct value |
| 310 | could forecast severe outcome. Unvaccinated older people over 60 years of age with specific |
| 311 | comorbidities are the high-risk groups associated with higher viral load and longer shedding |
| 312 | duration. People with mild-moderate symptoms were less contagious after symptom |
| 313 | resolution, but for severe or above patients, contagious characteristics could sustain for more |
| 314 | than 1 week. To prevent worsened consequences, timely using of antiviral drugs within 3 days |
| 315 | since onset was recommended targeting mild-moderate patients. |
| 316 | |

317 Ethics approval

- 318 This study was performed in compliance with an institutional review board protocol at
- Huashan Hospital (KY2022-596). Written informed consent was obtained from each
- 320 participant.

321 Availability of data and materials

322 The data analyzed are not publicly available as they contain personal information.

323 Funding

- 324 This work was supported by Shanghai Municipal Science and Technology Major
- 325 Project [HS2021SHZX001], the Key Program of the National Natural Science Foundation of
- 326 China [82161138018 and 82041010], Shanghai Science and Technology Committee
- 327 [20dz2260100, 20Z11901100] and Shanghai Hospital Development Center
- 328 [SHDC2020CR5010-002] and the Key Program of the National Science Foundation of China
- 329 [82130093].

330 Authors' contributions

- 331 Conception or design of the work: HJY, WHZ
- 332 Data collection: YL, JWA, SJG, HCZ, JPC, HYW, FS, YPW, JXZ, YW, RL, ZF, YLZ, XZ,
- 333 XYYX, XMY, YCZ

- 334 Data analysis and interpretation: JXZ, JWA, YL, FS, SJG, HCZ
- 335 Drafting the article: JXZ, JWA, YL
- 336 Critical revision of the article: HJY, WHZ, JXZ, JWA, YL, FS, SJG, HCZ, JJZ
- 337 Final approval of the version to be published: All of the authors.

338 Acknowledgements

- Hongjie Yu acknowledges financial support from the Key Program of the National Natural
- 340 Science Foundation of China (82130093). Wenhong Zhang, Juanjuan Zhang acknowledge
- 341 financial support from Shanghai Municipal Science and Technology Major Project
- 342 (HS2021SHZX001). Wenhong Zhang acknowledges financial support from the Key Program
- of the National Natural Science Foundation of China (82161138018 and 82041010),
- 344 Shanghai Science and Technology Committee (20dz2260100, 20Z11901100) and Shanghai
- 345 Hospital Development Center (SHDC2020CR5010-002). We thank all physicians and patients
- 346 for participating in this study. We appreciate all volunteers for helping collect data.

347

349 Figure legend

| 350 | Fig1. Characteristics of | viral shedding of total | participants. (A) C | value and negative |
|-----|--------------------------|-------------------------|---------------------|--------------------|
|-----|--------------------------|-------------------------|---------------------|--------------------|

- 351 proportion at each time point since initial detection. Solid and dashed lines indicate average
- 352 Ct value and proportion, respectively. Grey shadow indicates 95%CI. (B) Time distribution of
- 353 viral shedding duration. Vertical dashed line indicates median of viral shedding time. (C)
- 354 Correlation between peak Ct value and the time to reach peak since initial detection. Blue
- dashed lines indicate median of time at peak and the median of peak Ct value.

356 **Fig 2. Clinical severity-specific characteristics of viral shedding.** (A) Ct value at each

357 time point since initial detection. Solid line indicates average Ct value, shadow indicates 95%

358 CI. (B) Time distribution of viral shedding duration. Vertical dashed line indicates median of

359 viral shedding time. (C) Correlation between peak Ct value and the time to reach peak since

- 360 first positive PCR test. Vertical dashed line indicates median of time at peak and the median
- 361 of peak Ct value.

Fig 3. Age group-specific characteristics of viral shedding. (A) Ct value at each time point

- 363 since first positive PCR test. Solid line indicates average Ct value, shadow indicates 95% Cl.
- 364 (B) Time distribution of viral shedding duration. Vertical dashed line indicates median of viral
- 365 shedding time. (C) Correlation between peak Ct value and the time to reach peak since first
- 366 positive PCR test. Vertical dashed line indicates median of time at peak and the median of
- 367 peak Ct value.

Fig 4. Risk factors associated with peak viral load (A) and viral shedding duration (B).

369 The coefficients (dots) and 95% confidence intervals (95% CIs, line segments) were

| 370 | estimated from a multivariable regression analysis with an adjustment for gender, age, and |
|-----|--|
| 371 | comorbidities, and vaccination-infection status. Regression coefficients along with 95%CIs |
| 372 | are reported as solid dots and horizontal lines relative to the value of the regression intercept. |
| 373 | * p<0.05; ** p<0.01; *** p < 0.001. |
| 374 | Fig 5. Clinical severity-specific progression of positive proportion from initial detection |
| 375 | along with symptom statues. A: asymptomatic group; B: mild-moderate group; C: severe |
| 376 | group; D: clinical or death group. The above margined figure is the density of time intervals |
| 377 | between symptom onset since initial PCR detection (red) and the symptom resolution since |
| 378 | initial PCR detection (blue). The vertical dashed lines represented the median of time of onset |
| 379 | and symptom resolution date since initial detection. *: aggregated 20-30 days into a group, |
| 380 | other time points were not treated. |

| | | 1 1 2 | , | | | |
|------------------------|------------|-------------------|----------------|-------------|-------------------|----------------|
| | Total | Asymptomatic | Mild-moderate | Severe | Critical or death | |
| Characteristics | (n=48830) | (n=15165, 31%) | (n=33038, 68%) | (n=487, 1%) | (n=140, 0.29%) | <i>P</i> value |
| Gender | | | | | | <0.001 |
| Female | 30664 (63) | 10081 (66) | 20220 (61) | 271 (56) | 92 (66) | |
| Male | 18166 (37) | 5084 (34) | 12818 (39) | 216 (44) | 48 (34) | |
| Age (years) | | | | | | <0.001 |
| Median (IQR) | 45 (32-55) | 47 (34-56) | 43 (32-54) | 73 (65-85) | 78 (69-89) | |
| 0-17 | 1811 (4) | 565 (4) | 1245 (4) | 1 (0) | 0 (0) | |
| 18-59 | 39836 (82) | 11975 (79) | 27779 (84) | 66 (14) | 16 (11) | |
| 60-79 | 6536 (13) | 2480 (16) | 3750 (11) | 249 (51) | 57 (41) | |
| 80+ | 647 (1) | 145 (1) | 264 (1) | 171 (35) | 67 (48) | |
| Comorbidities | | | | | | <0.001 |
| | | | | | 5 (4) | |
| None | 38093 (78) | 12166 (80) | 25871 (78) | 51 (10) | | |
| | | | | | 101 (72) | |
| Hypertension | 6872 (14) | 1973 (13) | 4481 (14) | 317 (65) | | |
| | | | | | 67 (48) | |
| Diabetes | 2336 (5) | 708 (5) | 1397 (4) | 164 (34) | | |
| Cardiovascular disease | 1054 (2) | 227 (1) | 642 (2) | 117 (24) | 68 (49) | |
| | | | | | | |

382 Table 1. Baseline characteristics of enrolled participants by clinical severity.

| Hematologic diseases | 80 (0) | 11 (0) | 55 (0) | 10 (2) | 4 (3) |
|---------------------------------|-----------|-----------|-----------|----------|----------|
| Kidney disease (Level1) | 172 (0) | 36 (0) | 108 (0) | 16 (3) | 12 (9) |
| Kidney dialysis (Level2) | 215 (0) | 29 (0) | 77 (0) | 80 (16) | 29 (21) |
| Kidney transplantation (Level3) | 13 (0) | 1 (0) | 6 (0) | 5 (1) | 1 (1) |
| | | | | | 48 (34) |
| Neurological conditions | 412 (1) | 99 (1) | 187 (1) | 78 (16) | |
| Pneumonia | 522 (1) | 91 (1) | 390 (1) | 38 (8) | 3 (2) |
| | | | | | 0 (0) |
| HIV | 3 (0) | 1 (0) | 2 (0) | 0 (0) | |
| | | | | | 21 (15) |
| Malignancy | 345 (1) | 54 (0) | 227 (1) | 43 (9) | |
| | | | | | 8 (6) |
| Liver disease | 330 (1) | 58 (0) | 258 (1) | 6 (1) | |
| | | | | | 1 (1) |
| Rheumatism | 184 (0) | 30 (0) | 143 (0) | 10 (2) | |
| | | | | | 0 (0) |
| Rhinitis | 173 (0) | 17 (0) | 156 (0) | 0 (0) | |
| | | | | | 5 (4) |
| Psychotic condition | 86 (0) | 23 (0) | 56 (0) | 2 (0) | |
| Smoking history | 5096 (10) | 1236 (8) | 3827 (12) | 31 (6) | 2 (1) |
| Other underlying disease | 6524 (13) | 1336 (9) | 4738 (14) | 332 (68) | 133 (95) |
| Missing | 574 (1) | 289 (2) | 269 (1) | 14 (3) | 2 (1) |
| Vaccination type | | | | | |
| Unvaccinated | 5502 (11) | 1823 (12) | 3273 (10) | 328 (67) | 78 (56) |

<0.001

| Inactivated_Partial (1 dose) | 1483 (3) | 503 (3) | 968 (3) | 10 (2) | 2 (1) | |
|--------------------------------|----------------|----------------|----------------|----------------|---------------|--------|
| Inactivated_Full (2 doses) | 16848 (35) | 5273 (35) | 11516 (35) | 54 (11) | 5 (4) | |
| Inactivated_booster (3 doses) | 22694 (46) | 6804 (45) | 15838 (48) | 39 (8) | 13 (9) | |
| Ad_Full (1 dose) | 937 (2) | 335 (2) | 602 (2) | 0 (0) | 0 (0) | |
| Ad_booster (2 doses) | 442 (1) | 153 (1) | 287 (1) | 1 (0) | 1 (1) | |
| Protein_Partial (<3 doses) | 33 (0) | 5 (0) | 28 (0) | 0 (0) | 0 (0) | |
| Protein_Full (3 doses) | 292 (1) | 42 (0) | 248 (1) | 2 (0) | 0 (0) | |
| Mixed_Partial/Full (2/3 doses) | 12 (0) | 3 (0) | 9 (0) | 0 (0) | 0 (0) | |
| Mixed_Booster (3 doses) | 13 (0) | 4 (0) | 9 (0) | 0 (0) | 0 (0) | |
| Missing | 574 (1) | 220 (1) | 260 (1) | 53 (11) | 41 (29) | |
| Days since full vaccination | | | | | | |
| (median, IQR) | 320 (291, 346) | 321 (294, 346) | 319 (289, 346) | 320 (298, 349) | 328 (310,342) | <0.001 |
| Days since boost vaccination | | | | | | |
| (median, IQR) | 113 (92, 137) | 113 (93, 135) | 112 (92, 137) | 116 (93, 131) | 119 (98, 133) | <0.001 |
| | | | | | | |

383 All variables are expressed as n (%) except when indicated otherwise. IQR: interquartile range.

References

1 Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics.

Nature reviews Microbiology. 2023;21:147-61.

DOI:https://doi.org/10.1038/s41579-022-00822-w

2 Ling Y, Lu G, Liu F, Tan Y, Xu X, Wei D, et al. The Omicron BA.2.2.1

subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring

2022. Cell discovery. 2022;8:97.

DOI:https://doi.org/10.1038/s41421-022-00468-1

3 Commission SMH. The 177th press conference of COVID-19 in Shanghai.

2022.

4 Chen Z, Deng X, Fang L, Sun K, Wu Y, Che T, et al. Epidemiological

characteristics and transmission dynamics of the outbreak caused by the

SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. Lancet

Reg Health West Pac. 2022;29:100592.

DOI:https://doi.org/10.1016/j.lanwpc.2022.100592

5 Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral

kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in

Guangzhou, China. EClinicalMedicine. 2021;40:101129.

DOI:https://doi.org/10.1016/j.eclinm.2021.101129

> 6 Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh M, et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022;75:e1128-e36. DOI:https://doi.org/10.1093/cid/ciab721

7 Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infectious diseases.

2020;20:656-7. DOI:https://doi.org/10.1016/s1473-3099(20)30232-2

8 Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al.

SARS-CoV-2 viral load predicts COVID-19 mortality. The Lancet Respiratory

medicine. 2020;8:e70. DOI:https://doi.org/10.1016/s2213-2600(20)30354-4

9 Munker D, Osterman A, Stubbe H, Muenchhoff M, Veit T, Weinberger T, et al.

Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the

severity of disease in COVID-19 patients. The European respiratory journal.

2021;58. DOI:https://doi.org/10.1183/13993003.02724-2020

10 Jang J, Jeong H, Kim BH, An S, Yang HR, Kim S. Vaccine effectiveness in symptom and viral load mitigation in COVID-19 breakthrough infections in South Korea. PLoS One. 2023;18:e0290154.

DOI:https://doi.org/10.1371/journal.pone.0290154

11 Lin Y, Wu P, Tsang TK, Wong JY, Lau EHY, Yang B, et al. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected

with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective

observational study. Lancet Microbe. 2023;4:e722-e31.

DOI:https://doi.org/10.1016/S2666-5247(23)00146-5

12 Fryer HR, Golubchik T, Hall M, Fraser C, Hinch R, Ferretti L, et al. Viral

burden is associated with age, vaccination, and viral variant in a

population-representative study of SARS-CoV-2 that accounts for

time-since-infection-related sampling bias. PLoS Pathog. 2023;19:e1011461.

DOI:https://doi.org/10.1371/journal.ppat.1011461

13 Ravindran S, Gubbay JB, Cronin K, Sullivan A, Zygmunt A, Johnson K, et al. Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021. Open Forum Infect Dis. 2023;10:ofad282. DOI:https://doi.org/10.1093/ofid/ofad282

14 van Rossum C, Meijer C, van Weerdenburg IJ, Bowles EC, Rovers CP, Ten Oever J, et al. Low SARS-CoV-2 Cq values in healthcare workers with symptomatic COVID-19 infections, regardless of symptom severity, The Netherlands, January to August 2022. Euro Surveill. 2023;28.

DOI:https://doi.org/10.2807/1560-7917.ES.2023.28.4.2300007

15 Yang Y, Guo L, Yuan J, Xu Z, Gu Y, Zhang J, et al. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China. Lancet Microbe. 2023;4:e632-e41. DOI:https://doi.org/10.1016/S2666-5247 (23)00139-8

16 Theaux C, Martin Y, Montoto Piazza L, Wenk G, Notaristefano G, Mino L, et

al. Persistence of SARS-CoV-2 RNA shedding and infectivity in immunized

population: Prospective study along different epidemiological periods in

Argentina. PLoS One. 2023;18:e0285704.

DOI:https://doi.org/10.1371/journal.pone.0285704

17 Liu W, Gong F, Zheng X, Pei L, Wang X, Yang S, et al. Factors associated

with prolonged viral shedding of SARS-CoV-2 Omicron variant infection in

Shanghai: A multicenter, retrospective, observational study. J Med Virol.

2023;95:e29342. DOI:https://doi.org/10.1002/jmv.29342

18 A minimal common outcome measure set for COVID-19 clinical research.

The Lancet Infectious diseases. 2020;20:e192-e7.

DOI:https://doi.org/10.1016/S1473-3099(20)30483-7

19 Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al.

Infectious viral load in unvaccinated and vaccinated individuals infected with

ancestral, Delta or Omicron SARS-CoV-2. Nature medicine.

2022;28:1491-500. DOI:https://doi.org/10.1038/s41591-022-01816-0

20 Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston

DC, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron:

An investigation of hospital admissions and upper respiratory viral loads.

EBioMedicine. 2022;79:104008.

DOI:https://doi.org/10.1016/j.ebiom.2022.104008

21 Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, et al.

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron

Variant–Infected Vaccinees. Emerging Infectious Diseases. 2022;28:998-1001.

DOI:https://doi.org/10.3201/eid2805.220197

22 Bouton TC, Atarere J, Turcinovic J, Seitz S, Sher-Jan C, Gilbert M, et al.

Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications

for timing of release from isolation: a longitudinal cohort study. Clinical

infectious diseases : an official publication of the Infectious Diseases Society

of America. 2022. DOI:https://doi.org/10.1093/cid/ciac510

23 Utzon AN, Johansen IS, Bang LL, Pedersen RM, Andersen TE, Madsen

LW. Viral dynamics of SARS-CoV-2 in immunocompromised patients. Clin

Microbiol Infect. 2023;29:1087 e1- e3.

DOI:https://doi.org/10.1016/j.cmi.2023.05.013

24 Ergoren MC, Komurcu K, Tuncel G, Akan G, Ozverel CS, Dalkan C, et al. Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12-18 years group. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

2022;53:1937-40. DOI:<u>https://doi.org/10.1007/s42770-022-00820-3</u>

25 Ao Y, Li J, Wei Z, Wang Z, Tian H, Qiu Y, et al. Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China. Journal of Infection. 2022;85:573-607.

DOI:https://doi.org/10.1016/j.jinf.2022.07.027

> 26 Wu Q, Shi L, Li H, Huang S, Li H, Li L, et al. Viral RNA Load in Symptomatic and Asymptomatic COVID-19 Omicron Variant-Positive Patients. Can Respir J. 2022;2022:5460400. DOI:https://doi.org/10.1155/2022/5460400

27 Woodbridge Y, Amit S, Huppert A, Kopelman NM. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. Nature Communications. 2022;13:6706.

DOI:https://doi.org/10.1038/s41467-022-33096-0

28 Wu P, Lin Y, Tsang T, Wong J, Lau E, Yang B, et al. Viral shedding among symptomatic COVID-19 cases infected with the ancestral strain and Omicron BA.2. Research Square; 2022.

29 Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al.

Quantifying the impact of immune history and variant on SARS-CoV-2 viral

kinetics and infection rebound: A retrospective cohort study. eLife.

2022;11:e81849. DOI:https://doi.org/10.7554/eLife.81849

30 Choi G, Lim AY, Choi S, Park K, Lee SY, Kim JH. Viral shedding patterns of the symptomatic SARS-CoV-2 infection according to virus-type dominant periods and vaccination status in Gyeonggi Province, Korea. Epidemiology and health. 2022:e2023008. DOI:<u>https://doi.org/10.4178/epih.e2023008</u> 31 Kandel C, Lee Y, Taylor M, Llanes A, McCready J, Crowl G, et al. Viral dynamics of the SARS-CoV-2 Omicron Variant among household contacts with 2 or 3 COVID-19 vaccine doses. J Infect. 2022;85:666-70.

DOI:https://doi.org/10.1016/j.jinf.2022.10.027

> 32 Selvavinayagam ST, Yong YK, Joseph N, Hemashree K, Tan HY, Zhang Y, et al. Low SARS-CoV-2 viral load among vaccinated individuals infected with

Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and

BA.2 variants. Frontiers in public health. 2022;10:1018399.

DOI:https://doi.org/10.3389/fpubh.2022.1018399

33 Tassetto M, Garcia-Knight M, Anglin K, Lu S, Zhang A, Romero M, et al.

Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2

Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens -

San Francisco Bay Area, California, July 2021-March 2022. MMWR Morbidity

and mortality weekly report. 2022;71:1151-4.

DOI:https://doi.org/10.15585/mmwr.mm7136a3

34 von Wintersdorff CJH, Dingemans J, van Alphen LB, Wolffs PFG, van der Veer BMJW, Hoebe CJPA, et al. Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern. Scientific Reports. 2022;12:13922.

DOI:https://doi.org/10.1038/s41598-022-18279-5

35 China NHCotPsRo. Protocol for Prevention and Control of the Novel

Coronavirus Pneumonia (eighth edition). 2021.

36 Okita Y, Morita T, Kumanogoh A. Duration of SARS-CoV-2 RNA positivity

from various specimens and clinical characteristics in patients with COVID-19:

a systematic review and meta-analysis. Inflammation and regeneration.

2022;42:16. DOI:https://doi.org/10.1186/s41232-022-00205-x

37 Qassim SH, Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, et

al. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on

infectiousness of SARS-CoV-2 omicron infections. Journal of travel medicine.

2022;29. DOI:https://doi.org/10.1093/jtm/taac068

38 Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A,

et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta

(B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a

prospective, longitudinal, cohort study. The Lancet Infectious diseases.

2022;22:183-95. DOI:https://doi.org/10.1016/s1473-3099(21)00648-4

39 Wu J, Chen M, Tu C, Xiao Q, Liu X, Zhou X, et al. Clinical Course and

Factors Associated with Viral RNA Shedding and Radiologic Resolution in

Patients with COVID-19: a Retrospective Study. Clinical laboratory. 2022;68.

DOI:https://doi.org/10.7754/Clin.Lab.2021.210605

40 Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin

E. SARS-CoV-2, COVID-19 and the aging immune system. Nature Aging.

2021;1:769-82. DOI:https://doi.org/10.1038/s43587-021-00114-7

41 Kaseb AO, Mohamed YI, Malek AE, Raad, II, Altameemi L, Li D, et al. The

Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the

Incidence and Severity of COVID-19 Infection. Pathogens (Basel, Switzerland).

2021;10. DOI:https://doi.org/10.3390/pathogens10030379

42 Li H, Gao M, You H, Zhang P, Pan Y, Li N, et al. Association of

Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute

> Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023;76:e148-e54. DOI:<u>https://doi.org/10.1093/cid/ciac600</u> 43 Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. The Lancet Regional Health - Western Pacific. 2023:100694.

DOI:https://doi.org/https://doi.org/10.1016/j.lanwpc.2023.100694



С

В

Α





| Ι | |
|---|---|
| _ | • |

| Variables | | | | | | Mean (95% CI) |
|---------------------------------|----|---------|--------------|---------------|------|-------------------------|
| Gender | | | | | | |
| Male | | | | | | Ref |
| Female | | | 1 | - | | 27 48 (27 34 27 61)*** |
| | | | | | | 21.40 (21.04, 21.01) |
| 0_17 | | | i | + | | 28 47 (28 00 28 85)*** |
| 18_59 | | | | _ | | Rof |
| 60-79 | | | | | | 26 15 (25 94 26 37)*** |
| 80+ | | | - | | | 20.13 (20.34, 20.37) |
| Comorbidity | | | - | | | 24.02 (24.24, 20.00) |
| None | | | | | | Ref |
| Hypertension | | | | | | 26 47 (26 26 26 67)*** |
| Diabetes | | | | | | 27 34 (27 03 27 65) |
| Cardiovascular disease | | | | | | 26 77 (26 32 27 23) |
| Hematologic diseases | | | | _ | | 26.19 (24.71, 27.67) |
| Kidney disease (Level1) | | | | | | 25.93 (24.94, 26.93)* |
| Kidney dialysis (Level2) | | | | | | 20.39 (19.45, 21.33)*** |
| Kidney transplantation (Level3) | 3 | | | | | 23.43 (19.95, 26.91)* |
| Neurological conditions | ') | | | | | 25 23 (24 56, 25 90)*** |
| Pneumonia | | | - | - | | 27 45 (26 85, 28 05) |
| Malignancy | | | -8 | | | 26 73 (26 00, 27 47) |
| Rheumatism | | | | | | 26 10 (25 12 27 08)* |
| Psychotic condition | | | | | | 25 47 (23 96, 26 98)* |
| Vaccincation | | | | | | 20.11 (20.00, 20.00) |
| Unvaccinated | | | | | | Ref |
| Inactivated Partial (1 dose) | | | | _ | | 27 74 (27 31 28 16)** |
| Inactivated Full (2 doses) | | | | • | | 27.94 (27.70, 28.17)*** |
| Inactivated booster (3 doses) | | | | - | | 28.17 (27.94, 28.40)*** |
| Ad Full (1 dose) | | | | | | 28.25 (27.74, 28.76)*** |
| Ad booster (2 doses) | | | | . | | 27.85 (27.16, 28.55)* |
| Protein Partial (<3 doses) | | | - | _ | | 29.61 (27.09, 32.14) |
| Protein Full (3 doses) | | | | -8 | | 28.02 (27.22, 28.82)* |
| Mixed Partial/Full (2/3 doses) | | | | - | _ | 28.95 (24.04, 33.86) |
| Mixed_Booster (3 doses) | | | | | - | 33.73 (28.83, 38.64)** |
| | 15 | 20 P | 25 Peak C | 30 t value | 35 4 | 0 |

Mean (95% CI) Ref 7.14 (7.07, 7.21)* 6.75 (6.57, 6.93)*** -Ref 7.62 (7.51, 7.73)*** i 🖬 9.57 (9.24, 9.89)*** Ref 7.45 (7.35, 7.56)*** • 7.51 (7.35, 7.67)*** -7.63 (7.39, 7.88)*** --8.21 (7.39, 9.03)** ___ 8.22 (7.66, 8.78)*** 13.45 (12.85, 14.04)*** **_-**9.24 (7.21, 11.28)* 8.02 (7.64, 8.40)*** -8-7.64 (7.32, 7.95)*** -8-8.33 (7.92, 8.73)*** --8.02 (7.49, 8.55)*** 7.42 (6.62, 8.23) Ref 6.31 (6.10, 6.53)*** -6.46 (6.34, 6.58)*** 6.42 (6.30, 6.53)*** -6.49 (6.23, 6.74)*** -----6.75 (6.40, 7.11) --7.57 (6.35, 8.80) 7.87 (7.44, 8.30)*** -8-6.17 (3.95, 8.40) 5.37 (2.88, 7.85) 10 12 14 6 8 Viral shedding duration (days)

Shorter viral shedding Longer viral shedding

2

Higher viral load Lower viral load

В



